<DOC>
	<DOCNO>NCT02412306</DOCNO>
	<brief_summary>Open-label combine two-part multi-center clinical study evaluate efficacy , safety , tolerabillity blinatumomab adult pediatric Japanese subject R/R B-precursor ALL . The Phase 1b part investigate safety , efficacy , PK PD blinatumomab adult Japanse subects R/R B-precursor ALL determine MTD ( maximum tolerate dose ) adult pediatric subject . Once dose select Phase 1b part , Phase 2 part ass safety efficacy recommeded dose level blinatumomab identify Phase 1b portion study adult study population .</brief_summary>
	<brief_title>Study Blinatumomab Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Adult Subjects Key Age &gt; /= 18 year old enrollment Subjects Philadelphianegative Bprecursor ALL , follow : Relapsed refractory first line therapy first remission duration ≤ 12 month ; Relapsed refractory first salvage therapy ; Relapsed refractory within 12 month alloHSCT Greater 5 % blast bone marrow Pediatric Subjects Key Age &lt; 18 yearsold enrollment Relapsed/refractory disease , define one following : second later bone marrow relapse ; marrow relapse alloHSCT ; Refractory treatment : For subject first relapse : failure achieve CR follow full standard reinduction chemotherapy regimen For subject achieve first remission : failure achieve remission follow full standard induction regimen Greater 5 % blast bone marrow Karnofsky performance status ≥ 50 % subject ≥ 16 year Lansky performance status ≥ 50 % subject &lt; 16 year History malignancy ALL within 5 year prior start protocolspecified therapy exception : Malignancy treat curative intent know active disease present 5 year enrollment felt low risk recurrence treat physician Adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Adequately treat breast ductal carcinoma situ without evidence disease Prostatic situ without evidence disease Adequately treat mucosal gastric cancer mucosal colorectal cancer without evidence disease Diagnosis Burkitt 's Leukemia accord World Health Organization ( WHO ) classification History presence clinically relevant cental nervous system ( CNS ) pathology epilepsy , seizure , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis ; exception well control CNS leukemia Active ALL CNS ( confirm cerebrospinal fluid [ CSF analysis ] ) testes Isolated extramedullary disease Current autoimmune disease history autoimmune disease potential CNS involvement Autologous HSCT within 6 week prior start blinatumomab treatment AlloHSCT within 12 week prior start blinatumomab treatment Any active acute GraftversusHost Disease ( GvHD ) , grade 24 accord Glucksberg criterion active chronic GvHD require systemic treatment Any systemic therapy GvHD within 2 week prior start blinatumomab treatment Cancer chemotherapy within 2 week prior start blinatumomab treatment ( Intrathecal chemotherapy dexamethasone allow start blinatumomab treatment . Pediatric subject : Tyrosine kinase inhibitor and/or low dose maintenance therapy vinca alkaloid , mercaptopurine , methotrexate , glucocorticoid , intrathecal chemotherapy dexamethasone allow start blinatumomab ) Radiotherapy within 2 week prior start blinatumomab treatment Immunotherapy ( eg , rituximab ) within 6 week prior start blinatumomab treatment Subject receive prior antiCD19 therapy Eligibility alloHSCT time enrollment ( defined disease status , performance status availability donor ) Abnormal screen laboratory value define : AST ( SGOT ) and/or ALT ( SGPT ) and/or ALP &gt; = 5 x upper limit normal ( ULN ) Total bilirubin &gt; = 1.5 x ULN ( unless relate GilbertLs Meulengracht disease ) Creatinine &gt; = 1.5 ULN age , creatinine clearance &lt; 60 mL/min Known infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) Currently receive treatment another investigational device drug study , less 4 week since end treatment another investigational device drug study ( ) . Other investigational procedure participate study exclude . Subject know sensitivity immunoglobulins product component administer dose Subject likely available complete protocolrequired study visit procedure , include followup visit , and/or comply require study procedure best subject 's investigator 's knowledge Previous treatment blinatumomab Chemotherapy related toxicity ( exclude hematologic ) resolve &lt; = grade 2 Symptoms and/or clinical sign and/or radiological and/or sonographic sign indicate acute uncontrolled chronic infection , concurrent disease medical condition could exacerbate treatment would seriously complicate compliance protocol Pregnant breastfeeding woman , woman plan become pregnant breastfeed treatment additional time period discontinue treatment ( time period match require female contraception timeframe outline Section 6.12.1 ) Female subject childbearing potential unwilling use contraception outline Section 6.12.1 . Note : The pregnancy , breastfeed contraceptive requirement specific blinatumomab . The investigator responsible provide subject ( male female ) pregnancy breastfeed ( female ) avoidance requirement medication give study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Amgen</keyword>
</DOC>